The costly biotech drug blocks the growth of blood vessels that feed tumors. In July, a panel of experts voted 12-1 to recommend that FDA take back the approval, a rare step, because the benefits don't outweigh the risks.
Read More...
Read the complete post at http://www.npr.org/blogs/health/2010/08/16/129226084/avastin-breast-cancer-fda-approval?ft=1&f=103537970
Posted
Aug 16 2010, 06:04 AM
by
NPR Blogs: Shots - Health News Blog